Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

The biotechnology bubble machine

Nature Biotechnology volume 21, pages 355–356 (2003)Cite this article

The Biotech Advisor newsletter1 informs potential investors that biotechnology is “not the stuff of which bubbles are made.” The reason biotechnology is so exciting, and such a great investment, we are assured, is because...

“[I]t's for real. It's substantial. It's not going away. Biotech companies aren't run by twenty-something MBAs with green hair whose lifelong goal is to cash in and retire by age 30. Biotechnology companies are managed by some of the smartest—and most ethical—people in the world: scientists, physicians, and top managers who have dedicated their lives to improving human health. These folks are smart enough to realize that the only way they're going to get rich is if the stockholders get rich. And the only way the stockholders are going to get rich is if their products work—if they pass five to eight years of testing that costs upwards of $800 million, culminating in approval by the toughest regulatory agency on earth, the US Food and Drug Administration.”

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. The Biotech Advisor (Charter Financial Publishing Network, Shrewsbury, NJ, 2002).

  2. Ackerman, J. A promise unfulfilled in biotechnology: decline and fall of Alpha-Beta speaks volumes about pitballs of industry. The Boston Globe, February 10 (1999).

    Google Scholar 

  3. Leonhardt, D. Northeast Quietly Becomes a Health Care Corridor. New York Times, December 30 (2002).

  4. http://www.bio.org/news/stats.asp

  5. Lähteenmäki, R. & Fletcher, L. Nat. Biotechnol. 21, 551–555 (2002).

    Article  Google Scholar 

  6. Feldbaum, C.B., Convergence: Ernst & Young's Biotechnology Industry Report, Millennium Edition (E&Y, New York, 2000).

  7. http://www.bio.org/er/approveddrugs.asp

  8. Lee, K.L., et al. Ann. Intern. Med. 120, 876–885 (1994).

    Article  CAS  Google Scholar 

  9. Federal Trade Commission. Resolving Anticompetitive Concerns, FTC Clears $16 Billion Acquisition of Immunex Corp. by Amgen Inc. (FTC, Washington, DC, 2002).

Download references

Author information

Authors and Affiliations

  1. chief science officer of Boveran, San Ramon, CA

    David Rasnick

Authors
  1. David Rasnick
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rasnick, D. The biotechnology bubble machine. Nat Biotechnol 21, 355–356 (2003). https://doi.org/10.1038/nbt0403-355

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0403-355

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing